28541292|t|Long-range allosteric regulation of the human 26S proteasome by 20S proteasome - targeting cancer drugs
28541292|a|The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic activity is essential for cellular homeostasis. Thus, it is an attractive target for the development of chemotherapeutics. While the structural basis of core particle (CP) inhibitors is largely understood, their structural impact on the proteasome holoenzyme remains entirely elusive. Here, we determined the structure of the 26S proteasome with and without the inhibitor Oprozomib. Drug binding modifies the energy landscape of conformational motion in the proteasome regulatory particle (RP). Structurally, the energy barrier created by Oprozomib triggers a long-range allosteric regulation, resulting in the stabilization of a non-productive state. Thereby, the chemical drug-binding signal is converted, propagated and amplified into structural changes over a distance of more than 150 Ã… from the proteolytic site to the ubiquitin receptor Rpn10. The direct visualization of changes in conformational dynamics upon drug binding allows new ways to screen and develop future allosteric proteasome inhibitors.
28541292	0	10	Long-range	T081	C0392762
28541292	11	32	allosteric regulation	T044	C0002145
28541292	40	60	human 26S proteasome	T116,T126	C0286330
28541292	64	78	20S proteasome	T116,T126	C0208355
28541292	81	90	targeting	T169	C1521840
28541292	91	103	cancer drugs	T109,T121	C0003392
28541292	108	118	proteasome	T116,T126	C0208355
28541292	119	129	holoenzyme	T116,T126	C0282109
28541292	143	165	non-lysosomal protease	T116,T126	C0030940
28541292	171	191	proteolytic activity	T044	C0597304
28541292	195	204	essential	T080	C0205224
28541292	209	229	cellular homeostasis	T043	C2244223
28541292	246	256	attractive	T080	C2346874
28541292	257	263	target	T169	C1521840
28541292	272	283	development	T169	C1527148
28541292	287	304	chemotherapeutics	T109,T121	C0003392
28541292	327	332	basis	T169	C1527178
28541292	336	365	core particle (CP) inhibitors	T121	C0014432
28541292	406	412	impact	T080	C4049986
28541292	420	430	proteasome	T116,T126	C0208355
28541292	431	441	holoenzyme	T116,T126	C0282109
28541292	509	523	26S proteasome	T116,T126	C0286330
28541292	545	554	inhibitor	T121	C0014432
28541292	555	564	Oprozomib	T121	C2984209
28541292	566	578	Drug binding	T039	C0678749
28541292	579	587	modifies	T169	C0392747
28541292	599	608	landscape	T082	C0870781
28541292	612	633	conformational motion	T044	C1148560
28541292	641	651	proteasome	T116,T126	C0208355
28541292	652	671	regulatory particle	T026	C1325623
28541292	673	675	RP	T026	C1325623
28541292	696	710	energy barrier	T070	C1254365
28541292	722	731	Oprozomib	T121	C2984209
28541292	732	740	triggers	T201	C0032930
28541292	743	753	long-range	T081	C0392762
28541292	754	775	allosteric regulation	T044	C0002145
28541292	794	807	stabilization	T061	C1292828
28541292	848	869	chemical drug-binding	T039	C0678749
28541292	870	876	signal	T067	C1710082
28541292	880	889	converted	T169	C0439836
28541292	891	901	propagated	T067	C1254366
28541292	906	915	amplified	T067	C1521871
28541292	921	931	structural	T082	C0678594
28541292	932	939	changes	T169	C0392747
28541292	947	955	distance	T061	C1292828
28541292	984	1000	proteolytic site	T087	C1513411
28541292	1008	1026	ubiquitin receptor	T116,T129,T192	C0769158
28541292	1027	1032	Rpn10	T116,T192	C1869537
28541292	1038	1058	direct visualization	T033	C3846514
28541292	1062	1069	changes	T169	C0392747
28541292	1073	1096	conformational dynamics	T044	C1148560
28541292	1102	1114	drug binding	T039	C0678749
28541292	1134	1140	screen	T058	C0220908
28541292	1160	1170	allosteric	T044	C0002145
28541292	1171	1192	proteasome inhibitors	T121	C1443643